Ex­clu­sive: Backed by Il­lu­mi­na, Bro­ken String Bio­sciences rais­es $15M to find off-tar­get gene ed­its

Bro­ken String Bio­sciences has raised $15 mil­lion for its off-tar­get se­quenc­ing ser­vice for gene edit­ing com­pa­nies.

The Se­ries A round was led by Il­lu­mi­na Ven­tures and Mérieux Eq­ui­ty Part­ners and in­clud­ed HER­AN Part­ners, Ten­cent and Di­eter von Holtzbrinck Ven­tures. Mérieux’s Yoann Bon­namour and Il­lu­mi­na Ven­tures’ Ar­naud Autret have joined Bro­ken String’s board.

Bro­ken String’s se­quenc­ing plat­form ser­vice is tai­lored for gene edit­ing com­pa­nies and their con­tract re­search or­ga­ni­za­tions to find off-tar­get ed­its as they de­vel­op new ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER